Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Neurotrophic Keratitis > Study links high-dose proton therapy to potential neurotrophic keratitis risk
  • Neurotrophic Keratitis

Study links high-dose proton therapy to potential neurotrophic keratitis risk

Kelsey Moroz

Proton therapy for cephalic extraocular tumors does not significantly impact corneal sensitivity 6 months after treatment, as long as radiation doses to the cornea remain low, according to a study. However, a dose per fraction above 2 GyRBE may reduce corneal sensitivity.

The study included 43 patients (85 eyes) who underwent high-energy proton therapy, assessing their corneal sensitivity before and approximately 6 months after treatment.

Using the Cochet-Bonnet esthesiometer, researchers found no significant changes in corneal sensitivity, tear break-up time, or superficial punctate keratitis. The study reported mean maximal radiation doses of 10.7 GyRBE to the cornea and 42.0 GyRBE to its sensory innervation structures. Although overall corneal sensitivity remained stable, a dose per fraction exceeding 2 GyRBE was linked to a significant sensitivity decrease (P = 0.033).

The findings suggest that corneal damage risk is low when radiation doses are minimized. However, given previous reports of neurotrophic keratitis at corneal doses above 50 GyRBE, further studies are needed to clarify the long-term effects of high-dose proton therapy on corneal health.

Reference
Lebrun F, Thariat J, Marty PA, et al. Prospective Study of Corneal Sensitivity in Patients Treated With Proton Therapy for Extraocular Tumors. Cornea. 2024;doi: 10.1097/ICO.0000000000003781. Epub ahead of print. PMID: 39661121.

Share

Related Content

  • Neurotrophic Keratitis

Shelf-stable amniotic membrane improved outcomes in early-stage neurotrophic keratopathy

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Neurotrophic Keratitis

Early detection and targeted treatment strategies are critical for optimal outcomes in neurotrophic keratitis

  • Neurotrophic Keratitis

Amniotic membrane improves severe autoimmune-related KCS and NK outcomes

  • Neurotrophic Keratitis

Systemic abnormalities commonly found in neurotrophic keratopathy patients, study finds

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon